LabConnect Agrees to Acquire A4P Consulting

Stock.adobe.com

The mergers and acquisitions continue.

LabConnect announced that it has agreed to acquire A4P Consulting Ltd.¹ The latter company is a scientific consultancy firm that focuses on the following areas: bioanalytical and biosample project management, biomarker strategy, and logistic solutions in support of both pre-clinical and clinical trials. LabConnect will bring A4P Consulting’s assets under its umbrella in an effort to provide better services related to pre-clinical and clinical trial goals.

In a press release, A4P co-founder and chief executive officer Ian James, Ph. D., said, “A4P was founded over 12 years ago by four individuals from the pharma industry with a vision of how Bioanalytical and Logistical consultancy could be transformed. Bringing together our unique company model with LabConnect unlocks exciting opportunities to broaden the geographies we operate in and enhance our service offerings for our customers. I am excited for the future for both our customers and our valued staff."

In the same press release, LabConnect’s chief executive officer Dawn Sherman said, “With our complementary experience, expertise, and nimble working model, our clients have unprecedented access to leading edge scientific solutions to support their pre-clinical and clinical research. By joining forces with A4P, we further our mission to create healthier communities and improve patient lives by accelerating the development of medicines."

LabConnect partners with pharmaceutical companies, biotech companies, CROs, and NGOs across the globe, providing their clients with support for clinical trials. Due to the growing complexity of trials and the regulations surrounding them, firms like LabConnect help their clients complete their trials without hitting any avoidable roadblocks.

This is just the latest example of the life sciences industry embracing M&As in 2024. After the pandemic, there was a brief period where the industry saw a dip in M&As as companies managed their budgets. Starting last year, and continuing this year, the M&As came back full force. This is also the latest example of LabConnect expanding its business.

Last July, LabConnect announced a strategic partnership with Cleveland Clinic Laboratories, once again focused on improving its clinical trial capabilities.² LabConnect used this partnership to add Cleveland Clinic Laboratories extensive array of testing and assay validation services.

In a press release issued at the time, Sherman said, “With our shared mission to create healthier communities, we are excited about this alliance with Cleveland Clinic Laboratories to further accelerate the development of new medicines for patients around the world."

In the same press release, Cleveland Clinic’s chairman of pathology and laboratory medicine institute Brian Rubin, M.D., Ph. D., said, “This new collaboration will enable our organizations to leverage our complementary strengths to deliver cutting edge testing to an expanded patient base, furthering the mission of Cleveland Clinic to touch more lives.”

"By broadening access to expertise and quality care in pathology and laboratory medicine, we are able to continue evolving our services." said Ziad Peerwani, MD, Medical Director of Cleveland Clinic Laboratories. "Through this teamwork, we will support and elevate our work with local and global communities while creating the care for tomorrow."

Sources

1. LabConnect Acquires Scientific Consultancy A4P. LabConnect. April 22, 2024. https://www.prnewswire.com/news-releases/labconnect-acquires-scientific-consultancy-a4p-302122932.html
2. Cleveland Clinic and LabConnect Announce Strategic Alliance. LabConnect. July 11, 2024. Accessed April 22, 2024. https://www.prnewswire.com/news-releases/cleveland-clinic-and-labconnect-announce-strategic-alliance-301873572.html